VISTAGEN THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $145.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-14
- VISTAGEN THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $145.00K, a 12.40% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $138.00K, a 9.52% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $135.00K, a 10.66% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $132.00K, a 10.00% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2026 was $534.00K, a 10.10% increase from fiscal 2025.
- VISTAGEN THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $485.00K, a 9.98% increase from fiscal 2024.
- VISTAGEN THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $441.00K, a 9.70% increase from fiscal 2023.
- VISTAGEN THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $402.00K, a 27.91% decline from fiscal 2022.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $145.00K 10-Q · filed 2026-08-14 | $283.00K derived: sum of 2 quarters · filed 2026-08-14 | $418.00K derived: sum of 3 quarters · filed 2026-08-14 | $550.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | $273.00K derived: sum of 2 quarters · filed 2026-06-15 | $405.00K derived: sum of 3 quarters · filed 2026-06-15 | $534.00K 10-K · filed 2026-06-15 | |||
| 2025-12-31 | $135.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $267.00K derived: sum of 2 quarters · filed 2026-02-12 | $396.00K 10-Q · filed 2026-02-12 | $522.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-09-30 | $132.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $261.00K 10-Q · filed 2025-11-13 | $387.00K derived: sum of 3 quarters · filed 2026-08-14 | $509.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $129.00K 10-Q · filed 2026-08-14 | $255.00K derived: sum of 2 quarters · filed 2026-08-14 | $377.00K derived: sum of 3 quarters · filed 2026-08-14 | $497.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | $248.00K derived: sum of 2 quarters · filed 2026-06-15 | $368.00K derived: sum of 3 quarters · filed 2026-06-15 | $485.00K 10-K · filed 2026-06-15 | |||
| 2024-12-31 | $122.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $242.00K derived: sum of 2 quarters · filed 2026-02-12 | $359.00K 10-Q · filed 2026-02-12 | $473.00K derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2024-09-30 | $120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $237.00K 10-Q · filed 2025-11-13 | $351.00K derived: sum of 3 quarters · filed 2025-11-13 | $463.00K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $117.00K 10-Q · filed 2025-08-07 | $231.00K derived: sum of 2 quarters · filed 2025-08-07 | $343.00K derived: sum of 3 quarters · filed 2025-08-07 | $451.00K derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-17 | $226.00K derived: sum of 2 quarters · filed 2025-06-17 | $334.00K derived: sum of 3 quarters · filed 2025-06-17 | $441.00K 10-K · filed 2025-06-17 | |||
| 2023-12-31 | $112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $220.00K derived: sum of 2 quarters · filed 2025-02-13 | $327.00K 10-Q · filed 2025-02-13 | $431.10K derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2023-09-30 | $108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $215.00K 10-Q · filed 2024-11-07 | $215.30K 10-Q · filed 2023-11-09 | $319.10K derived: sum of 3 quarters · filed 2024-11-07 | $420.70K derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $107.00K 10-Q · filed 2024-08-13 | $106.50K 10-Q · filed 2023-08-10 | $211.10K derived: sum of 2 quarters · filed 2024-08-13 | $312.70K derived: sum of 3 quarters · filed 2024-08-13 | $412.00K derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $104.10K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-11 | $205.70K derived: sum of 2 quarters · filed 2024-06-11 | $305.00K derived: sum of 3 quarters · filed 2024-06-11 | $402.00K 10-K · filed 2024-06-11 | $401.70K 10-K · filed 2023-06-28 | ||
| 2022-12-31 | $101.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | $200.90K derived: sum of 2 quarters · filed 2024-02-13 | $297.90K 10-Q · filed 2024-02-13 | $392.70K derived: sum of 4 quarters · filed 2024-02-13 | |||
| 2022-09-30 | $99.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-09 | $196.30K 10-Q · filed 2023-11-09 | $291.10K derived: sum of 3 quarters · filed 2023-11-09 | $563.40K derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $97.00K 10-Q · filed 2023-08-10 | $191.80K derived: sum of 2 quarters · filed 2023-08-10 | $464.10K derived: sum of 3 quarters · filed 2023-08-10 | $560.30K derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $94.80K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $367.10K derived: sum of 2 quarters · filed 2023-06-28 | $463.30K derived: sum of 3 quarters · filed 2023-06-28 | $557.60K 10-K · filed 2023-06-28 | |||
| 2021-12-31 | $272.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-07 | $368.50K derived: sum of 2 quarters · filed 2023-02-07 | $462.80K 10-Q · filed 2023-02-07 | $555.30K derived: sum of 4 quarters · filed 2023-02-07 | |||
| 2021-09-30 | $96.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-10 | $190.50K 10-Q · filed 2022-11-10 | $190.50K 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $94.30K 10-Q · filed 2022-08-11 | $186.80K derived: sum of 2 quarters · filed 2022-08-11 | |||||
| 2021-03-31 | $92.50K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23 | $360.00K 10-K · filed 2022-06-23 | |||||
| 2020-12-31 | $267.50K 10-Q · filed 2022-02-10 | ||||||
| 2020-09-30 | $176.70K 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | $87.50K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $335.40K 10-K · filed 2021-06-29 | ||||||
| 2019-03-31 | $0.00 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |